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Background
The threat of pandemic A/H1N1 influenza remains a mat-
ter of considerable public concern. Recent influenza out-
breaks underline the importance of rapid production of a
reserve of vaccine sufficient for pandemic and interpan-
demic periods. Traditional vaccines intended for seasonal
influenza do not satisfy this demand, because they are
unable to induce cross-reactive antibodies to pandemic flu.
Live influenza vaccines made in the cell culture offer
potential advantages because it is possible to produce a
considerable amount of these vaccines over a short per-
iod. Their use eliminate concerns about allergic reac-
tions to egg proteins, and they allow the antigenic
composition of the vaccine to be closer to the circulat-
ing influenza virus strains.
The goal of this work was to develop a live attenuated
vaccine against pandemic influenza, Vector-Flu, derived
from cold-adapted strain A/17/California/2009/38
(H1N1) and to study the immunogenic and protective
properties of the vaccine using ferrets and mice.
Materials and methods
Cell culture
MDCK from Cell Culture Collection of SRC VB VEC-
TOR. Cells were passed in serum-free SFM4MegaVir
medium (USA). The characteristics of the MDCK cell
line were studied in accordance with WHO [1].
Viruses
The vaccine strain A/17/California/2009/38(H1N1) was
generated at the Institute of Experimental Medicine (St.
Petersburg, Russia) by reassortment of the cold-adapted
attenuated A/Leningrad/134/17/57 (H2N2) master
donor virus with the pandemic strain A/California/7/
2009 (H1N1). The A/Chita/3/2009(H1N1) influenza
virus was obtained from VECTOR’s Collection of
Microorganisms.
Animals
Female ferrets were 4–5 month old and were obtained
from the Animal Farm Rodniki (Pushkino, Moscow
region, Russia).
Determination of influenza virus infectious activity
The infectious activity of influenza virus was determined
b yt i t r a t i o ni n1 0 –12-day-old chick embryos. 10-fold
dilutions (0.2 ml) of virus-containing fluid were inocu-
lated into the allantoic cavity of chick embryos. The
embryos were incubated for 48 hours at a temperature
of 35°C. After the incubation, the allantoic fluid was
harvested from the embryos to determine the virus
infectious activity by agglutination reaction with 1%
chicken red blood cells. The virus titer was calculated
according to the Reed–Muench method and expressed
as log EID50/0.2 ml [2].
Control of immunogenicity of the Vector-Flu vaccine
18 ferrets were anesthetized to take blood samples (5
ml) from the caudal vein; they were then immunized
with 200 µl of the Vector-Flu vaccine at 6.6–6.8 log
EID50 dose delivered into each nostril. One ferret sub-
g r o u pw a si m m u n i z e dw i t has i n g l ed o s ea n da n o t h e r
subgroup received two doses of vaccine with a 10-day
interval between vaccinations. At day 21 after the last
immunization, the sedated animals were bled from the
caudal vein to obtain sera and the antibody titers were
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neutralization assays.
Hemagglutination Inhibition (HAI) test. HAI was per-
formed by a routine technique [3] with some modifica-
tions. The assayed sera were pre-treated with the
receptor destroying enzyme (RDE). The hemagglutina-
tion reaction was performed with 1% chicken red blood
cells (RBC). The HAI titer was determined as the reci-
procal dilution of the last row which contained non-
agglutinated RBC.
Microneutralization assay. The assay was performed
in compliance with the WHO guidelines [3] with some
modifications. MDCK cells supplemented with equal
volumes of serum and influenza virus were mixed and
incubated in 5% CO2 at 37°C. The presence of the virus
w a sd e t e c t e db ye n z y m ei m m u n o a s s a yu s i n gt h em o n o -
clonal antibodies to type A influenza virus NP protein
(CDC, Atlanta). Neutralizing antibody titer was defined
as reciprocal of the highest serum dilution that provided
50% inhibition of the virus growth in cell culture.
Results
The live MDCK-derived Vector-Flu vaccine was pro-
duced in accordance with the established production
specifications. Ever in Russia, based on MDCK cell line,
we have developed seed and working banks of cells; cell
banks are certified in accordance with WHO recom-
mendations [1].
The vaccine production technology involved the fol-
lowing steps:
￿ microcarrier cultivation of MDCK cells in fermenters
in serum-free medium;
￿ A/17/California/2009/38 (H1N1) virus growth in the
cell culture;
￿ virus-containing fluid collection and purification;
￿ introduction of stabilizers and biodegradable
polymer;
￿ freeze-drying; ready-to-use vaccine formulation
production.
7 laboratory batches of vaccine Vector-Flu have been
produced and certified; they have specific activity index
as 7.33-7.5 lg EID50/ml.
Ferret immune response data to administration of the
live MDCK-derived Vector-Flu vaccine are listed in the
Table 1. High serum titers of the ferrets immunized
with A/H1N1 pandemic influenza virus strain (up to
1:5120 by HAI after a single dose vaccination) should be
noted. Second dose vaccination with the A/17/Califor-
nia/2009/38 (H1N1) vaccine strain increased the HAI
titers from 1:1097 to 1:1493, while the geometric mean
titers (GMTs) determined by microneutralization assay,
went from 1:1016 to 1:2032, respectively. The Vector-
Flu vaccine is immunogenic against both A/Chita/3/
2009 strain of pandemic A/H1N1 influenza virus iso-
lated in Russia, and the pandemic influenza virus strain
A/California/7/2009.
We have developed the vaccine production pilot sche-
dule and have prepared the set of specification docu-
ments for vaccine registration application submission to
Ministry of health and social development of Russia. We
are planning to do the clinical trials Phase I in Russia in
2011.
Conclusions
We have developed live cultural influenza vaccine pro-
duction technology. The technology used for pandemic
influenza vaccine Vector-Flu production has a versatile
use mode, and it could be used for growing live cultural
vaccines based on the other influenza virus subtypes.
We have obtained the patent of Russia #2330885 for the
developed technology.
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Table 1 The titers of ferret blood serum to A/H1N1 influenza virus strains before and after immunization with the
Vector-Flu vaccine determined by HAI and microneutralization assay.
Serological method HAI Microneutralization
Influenza virus strain A/Chita/3/2009 A/California/7/2009 A/Chita/3/2009 A/California/7/2009
Number of vaccinations 0 1 2 0 1 2 0 1 2 0 1 2
GMT
a over the group <20 2987 2560 <20 818 3556 <40 1636 5120 <40 924 1422
SD of the GMT 1693 1568 718 1538 723 0 649 699
aMean geometric titer
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